Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Bispecific/pharmacology"'
Autor:
Bram Herpers, Berina Eppink, Mark I. James, Carme Cortina, Adrià Cañellas-Socias, Sylvia F. Boj, Xavier Hernando-Momblona, Dominik Glodzik, Rob C. Roovers, Marc van de Wetering, Carina Bartelink-Clements, Vanessa Zondag-van der Zande, Jara García Mateos, Kuan Yan, Lucia Salinaro, Abdul Basmeleh, Szabolcs Fatrai, David Maussang, Jeroen J. Lammerts van Bueren, Irene Chicote, Garazi Serna, Laia Cabellos, Lorena Ramírez, Paolo Nuciforo, Ramon Salazar, Cristina Santos, Alberto Villanueva, Camille Stephan-Otto Attolini, Elena Sancho, Hector G. Palmer, Josep Tabernero, Michael R. Stratton, John de Kruif, Ton Logtenberg, Hans Clevers, Leo S. Price, Robert G. J. Vries, Eduard Batlle, Mark Throsby
Publikováno v:
Nature cancer, 3(4), 418-436
Patient-derived organoids (PDOs) recapitulate tumor architecture, contain cancer stem cells and have predictive value supporting personalized medicine. Here we describe a large-scale functional screen of dual-targeting bispecific antibodies (bAbs) on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd6787d32a1a24821ce4603c0851f3e6
https://pure.knaw.nl/portal/en/publications/06b7bea9-adb4-44dc-9013-631489b16e6a
https://pure.knaw.nl/portal/en/publications/06b7bea9-adb4-44dc-9013-631489b16e6a
Publikováno v:
Clinical and Translational Medicine. 12(8)
BACKGROUND: The CD47-signal regulatory protein alpha (SIRPα) 'don't eat me' signalling axis is perhaps the most prominent innate immune checkpoint to date. However, from initial clinical trials, it is evident that monotherapy with CD47-SIRPα blocki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dris___01423::b5a76314655edb49dd66b1f6cbe6839b
https://doi.org/10.1002/ctm2.943
https://doi.org/10.1002/ctm2.943
Publikováno v:
Clinical and Translational Medicine. 12
BACKGROUND: The CD47-signal regulatory protein alpha (SIRPα) 'don't eat me' signalling axis is perhaps the most prominent innate immune checkpoint to date. However, from initial clinical trials, it is evident that monotherapy with CD47-SIRPα blocki
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::470fe21f2abb0f15b570c98bc5941043
https://doi.org/10.1002/ctm2.943
https://doi.org/10.1002/ctm2.943